Oji Holdings Acquires LTL Pharma to Bolster Pharmaceutical Business

Oji Holdings Corporation announced the acquisition of all shares in LTL Pharma Co., Ltd., a Tokyo-based pharmaceutical manufacturer and seller under Unison Capital Co., Ltd. The deal was executed through a special purpose company formed by Oji Holdings and Unison Capital No. 6 Investment Limited Partnership. Consequently, LTL Pharma becomes an affiliate of Oji Holdings. This move supports Oji Holdings' Medium-Term Management Plan 2027, emphasizing wood biomass as a core business. Wholly owned subsidiary Oji Pharma Co., Ltd. focuses on R&D for veterinary medicines and pharmaceuticals from natural capital. Oji Pharma's sulfated hemicellulose gained approval as a veterinary active ingredient in Australia in 2025, while other products advance toward commercialization, including a homocystinuria treatment (betaine) approved as a generic in Japan in February 2026. Established in 2016, LTL Pharma delivers stable long-listed prescription pharmaceuticals, prioritizing safety and quality through efficient management. The investment leverages LTL's expertise to speed Oji Pharma's market entry and wood biomass growth. LTL, located in Shinjuku-ku, Tokyo, handles manufacturing, sales, import, and export of prescription drugs. Unison Capital has held all shares since inception, aiding LTL's expansion. Oji Group commits to nature-positive contributions in medical and healthcare fields. The acquisition will have minimal impact on fiscal year ending March 31, 2026 performance.